Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29638516 | 0.85 | PARP1 (0.54) | PARP1CHEK1PIM1RPS6KA3SMN1; SMN2 | |
| SCHEMBL13003705 | 0.85 | PARP1 (0.54) | PARP1CHEK1PIM1RPS6KA3SMN1; SMN2 | |
| SCHEMBL1584889 | 0.79 | PIM1 (0.56) | CHEK1PIM1RPS6KA3SMN1; SMN2ALDH1A1 | |
| SCHEMBL8622177 | 0.79 | ACVR1 (0.46) | PARP1CHEK1PIM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL216175 | 0.78 | PARP1 (0.54) | PARP1CHEK1PIM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2191063 | 0.78 | PARP1 (0.54) | PARP1CHEK1KDM4EALDH1A1KMT2A | |
| SCHEMBL2574527 | 0.78 | LMNA (0.57) | PARP1KDM4EHSD17B10ALDH1A1MEN1 | |
| SCHEMBL8700858 | 0.78 | PARP1 (0.54) | PARP1RPS6KA3SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL2191001 | 0.78 | PARP1 (0.54) | PARP1CHEK1PIM1RPS6KA3RXFP1 | |
| SCHEMBL8976527 | 0.77 | IP6K1 (0.58) | SMN1; SMN2KDM4EHSD17B10ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466942-A | Chiral secondary phosphine oxide compound, chiral quinazolinone/pyrimidinone ring derivative based on chiral secondary phosphine oxide compound and application of chiral quinazolinone/pyrimidinone ring derivative | 中山大学 | 2024-01-30 | — | — | CN | disclosed |
| EP-3103799-A1 | QUINAZOLINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2163546-B1 | Quinazoline derivatives | PFIZER PROD INC (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20130029939-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-8318932-B2 | Process for producing 4-aminoquinazoline compound | UBE INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| EP-1481971-B1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | UBE INDUSTRIES (JP) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011131610-A1 | HEAT TRANSFER MEDIUM BASED ON SULPHUR AND USE OF THE HEAT TRANSFER MEDIUM | SIEMENS AKTIENGESELLSCHAFT (DE) | 2011-10-27 | — | — | WO | disclosed |
| EP-2295415-A1 | Quinazoline derivatives | OSI Pharmaceuticals, Inc. (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2163546-A1 | Quinazoline derivatives | Pfizer Products Incorporated (US) | 2010-03-17 | — | — | EP | disclosed |
| US-RE41065-E1 | Alkynl and azido-substituted 4-anilinoquinazolines | PFIZER, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-5747498-A | Alkynyl and azido-substituted 4-anilinoquinazolines | PFIZER INC. (US) | 1998-05-05 | — | — | US | disclosed |
| WO-1998010767-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | SUGEN, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| EP-0817775-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| WO-1996030347-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| WO-1995024190-A2 | RECEPTOR TYROSINE KINASE INHIBITORS FOR INHIBITING CELL PROLIFERATIVE DISORDERS AND COMPOSITIONS THEREOF | SUGEN, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
| US-4223143-A | PYRAZOLO-QUINAZOLIN-ONES, CONTROLLING URIC ACID CONCENTRATION, GOUT, XANTHINE OXIDASE | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1980-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029939-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, HK1 | PARP1 3497/4885CHEK1 3493/4885PIM1 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.